Literature DB >> 15102686

MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis.

Stephan E Baldus1, Stefan P Mönig, Sandra Huxel, Stephanie Landsberg, Franz-Georg Hanisch, Katja Engelmann, Paul M Schneider, Jürgen Thiele, Arnulf H Hölscher, Hans P Dienes.   

Abstract

PURPOSE: Overexpression of MUC1 and cytosolic interaction of the mucin with beta-catenin are claimed to be involved in colorectal carcinogenesis. In vitro data published recently suggest that MUC1 overexpression results in an increase of steady state levels of nuclear beta-catenin. We tried to elucidate the coexpression of both molecules in colorectal cancer to demonstrate possible correlations with clinical, pathological, and prognostic data. EXPERIMENTAL
DESIGN: An immunohistochemical double staining study was performed to characterize the expression and subcellular distribution of MUC1 and beta-catenin in a series of 205 patients with colorectal carcinoma. The results were correlated with clinicopathological variables as well as overall survival.
RESULTS: MUC1 was strongly expressed in the tumor center and at the invasion front in approximately 50% of the cases. Similar results were obtained with regard to nuclear accumulation of beta-catenin at the invasive tumor parts. MUC1 protein expression in the tumor center correlated significantly with a low grade of differentiation, and nuclear beta-catenin in the tumor periphery was more frequent in carcinomas of the left colon and rectum. Overexpression of MUC1 and beta-catenin, as well as their nuclear coexpression at the invasion front correlated with a worse overall survival in an univariate analysis. However, only pathological tumor-node-metastasis staging and MUC1 at the invasion front revealed as independent prognostic factors.
CONCLUSIONS: These results suggest that MUC1 and beta-catenin are coexpressed at the invasion front of colorectal carcinomas and that this feature is associated with an accelerated course of disease and worse prognosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15102686     DOI: 10.1158/1078-0432.ccr-03-0163

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  75 in total

1.  Beta-catenin inhibits melanocyte migration but induces melanoma metastasis.

Authors:  S J Gallagher; F Rambow; M Kumasaka; D Champeval; A Bellacosa; V Delmas; L Larue
Journal:  Oncogene       Date:  2012-06-04       Impact factor: 9.867

2.  MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling.

Authors:  Jian Ren; Deepak Raina; Wen Chen; Guilan Li; Lei Huang; Donald Kufe
Journal:  Mol Cancer Res       Date:  2006-11       Impact factor: 5.852

Review 3.  MUC1 and colorectal cancer pathophysiology considerations.

Authors:  Yaron Niv
Journal:  World J Gastroenterol       Date:  2008-04-14       Impact factor: 5.742

4.  Overexpression of nuclear β-catenin in rectal adenocarcinoma is associated with radioresistance.

Authors:  Lin Wang; Xiao-Mei Zhang; Zhen Li; Xi-Jun Liu; Jie Chai; Guang-Yong Zhang; Yu-Feng Cheng
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

5.  Anti-proliferative effect of auriculataoside A on B16 melanoma 4A5 cells by suppression of Cdc42-Rac1-RhoA signaling protein levels.

Authors:  Weicheng Wang; Souichi Nakashima; Seikou Nakamura; Yoshimi Oda; Hisashi Matsuda
Journal:  J Nat Med       Date:  2019-01-09       Impact factor: 2.343

6.  Up-regulation of alpha-catenin is associated with increased lymph node involvement in colorectal cancer.

Authors:  Adam Elzagheid; Abdelbaset Buhmeida; Eija Korkeila; Yrjö Collan; Kari Syrjänen; Seppo Pyrhönen
Journal:  World J Gastroenterol       Date:  2008-08-21       Impact factor: 5.742

7.  Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status.

Authors:  A Lugli; I Zlobec; K Baker; P Minoo; L Tornillo; L Terracciano; J R Jass
Journal:  J Clin Pathol       Date:  2006-06-30       Impact factor: 3.411

8.  Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma.

Authors:  J Cho; S Y Kim; Y J Kim; M H Sim; S T Kim; N K D Kim; K Kim; W Park; J H Kim; K-T Jang; J Lee
Journal:  Clin Transl Oncol       Date:  2017-04-18       Impact factor: 3.405

Review 9.  WNT signalling pathways as therapeutic targets in cancer.

Authors:  Jamie N Anastas; Randall T Moon
Journal:  Nat Rev Cancer       Date:  2013-01       Impact factor: 60.716

10.  Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors.

Authors:  Inti Zlobec; Alessandro Lugli
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.